Glenmark Pharmaceuticals announced the upcoming launch of Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials. Glenmark's Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Halaven® Injection, 1 mg/2 mL (0.5 mg/mL), of Eisai, Inc., and the company will begin distribution in September 2025.
According to IQVIA® sales data for the 12-month period ending July 2025, the Halaven® Injection, 1 mg/2 mL (0.5 mg/mL) market achieved annual sales of approximately $66.3 million*.
Commenting on the launch, Marc Kikuchi, President & Business Head, North America, said, "We are pleased to announce the launch of Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials. As the first complex generic in our portfolio, this launch marks both our commitment to growing our portfolio of products within the institutional channel and reinforces our dedication to bring quality and affordable alternatives to market for patients in need."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!